An experimental genetic treatment called VERVE-101 can deactivate a cholesterol-raising gene in people with hypercholesterolemia, Meghan Rosen reported in “Base editing can lower cholesterol” (SN: 1/27/24, p. 8).
Rosen wrote that researchers are testing to see what dosage of VERVE-101 is most effective. Given that the treatment edits a gene, reader Linda Ferrazzara wondered why the dose matters.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.